News Sentiment

SNTI sentiment intelligence

Senti Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.44 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-57.6% over one week, -53.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

$Senti Biosciences (SNTI.US)$

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -57.6% Price reacting lower
Trend fit Trend inactive -53.1% over four weeks
Fair value -85.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 40
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 9
TradingView 8
TradingKey 5
Investing.com 3
Moomoo 2
Investing.com Nigeria 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 14
Deals and strategy 5
Analyst action 3
Guidance 2
Macro sensitivity 2
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Stock Titan Direct company coverage

Senti Biosciences Holdings, Inc. SEC Filing (Jul 21, 2026)

This article reports on an ARS SEC filing by Senti Biosciences Holdings, Inc. (SNTI) on July 21, 2026. The filing has a low impact and neutral sentiment, and was accepted by the SEC EDGAR at 05:18 PM on the same date. The article also provides recent news and other SEC filings re

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 22:10
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 13D/A Senti Biosciences Holdings For: 16 July By Investing.com

This article from Investing.com reports on a Form 13D/A filing related to Senti Biosciences Holdings, specifically for activity on July 16. It notes a -4.94% change for SNTI. The content primarily focuses on financial market data and investment-related topics, including stock per

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 12:10
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Form S-3/A Senti Biosciences Holdings Inc For: 16 July

This article announces the filing of Form S-3/A by Senti Biosciences Holdings Inc. on July 16, 2026. This SEC filing is typically related to registering securities for offering, indicating potential capital-raising activities for the company. The brief notice highlights the immed

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 00:09
Source
Investing.com Nigeria
Investing.com South Africa Direct company coverage

Form S-3/A Senti Biosciences Holdings Inc For: 16 July By Investing.com

This article from Investing.com announces the filing of Form S-3/A by Senti Biosciences Holdings Inc. The filing date is noted as July 16, and the article provides no further details beyond this announcement. The piece includes financial data, market indices, and other investment

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 18:14
Source
Investing.com South Africa
Stock Titan Direct company coverage

Senti Biosciences (SNTI) backer plans merger and $6M funding

Celadon-affiliated entities, holding a 54.6% stake in Senti Biosciences (SNTI), have reported a merger agreement with Senti Biosciences Holdings. This merger involves the acquisition of Senti's Gene-Circuit-enabled pipeline, including SENTI-202 rights, through Parent (Celadon Par

Tone
Positive 67/100
Event
Deals and strategy
Published
16 Jul 2026 18:10
Source
Stock Titan
Stock Titan Direct company coverage

Senti Bio Stockholders Could Receive Up to $60M From SENTI-202

Senti Biosciences Holdings (NASDAQ: SNTI) announced a strategic transaction where its Gene-Circuit-enabled pipeline, including SENTI-202, will be acquired by a new private biotechnology company controlled by its largest investor, Celadon. In return, SBH equity holders will receiv

Tone
Negative 20/100
Event
Market update
Published
16 Jul 2026 01:10
Source
Stock Titan
Market source Direct company coverage

Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Te

Senti Biosciences Holdings, Inc. (SBH) announced a strategic transaction where a newly formed private company, NewCo, will acquire SBH's Gene-Circuit-enabled pipeline, including SENTI-202. In return, SBH equity holders will receive a contingent value right (CVR) providing up to $

Tone
Positive 70/100
Event
Market update
Published
15 Jul 2026 11:48
Source
Market source
TradingView Direct company coverage

Senti Biosciences to Divest Operating Business to Celadon Affiliate; Holders Get Up to $60M CVRs

Senti Biosciences has announced a merger agreement with a Celadon Partners affiliate to divest substantially all of its existing business and pipeline. Senti will remain public, retaining certain IP and early-stage programs, while stockholders could receive up to $60 million in c

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 11:48
Source
TradingView
Quiver Quantitative Direct company coverage

Senti Biosciences Holdings Announces Strategic Spin-Off of Gene-Circuit Pipeline and Plans Focus on Regulator Dial Platform

Senti Biosciences Holdings (SBH) announced a strategic spin-off of its Gene-Circuit pipeline, including SENTI-202, into a new private company, NewCo. SBH will now focus on its Regulator Dial platform for controllable genetic therapies, while stockholders could receive up to $60 m

Tone
Positive 62/100
Event
Market update
Published
15 Jul 2026 11:42
Source
Quiver Quantitative
TradingView Direct company coverage

Price to book forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI

This article provides the "Price to book forward" value for Senti Biosciences Holdings, Inc. (NASDAQ: SNTI). It appears to be a stub or a data point from a financial platform like TradingView, indicating that the specific financial metric for the company at a certain period is av

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 10:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI

This article provides a financial metric—enterprise value to EBIT forward—for Senti Biosciences Holdings, Inc. (NASDAQ: SNTI). It appears to be a data point from TradingView's financial section, offering a snapshot of this specific valuation metric without further analytical comm

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 09:11
Source
TradingView
TradingView Direct company coverage

Senti Biosciences Holdings Inc Actuals & Estimates (NASDAQ:SNTI)

This article provides an overview of Senti Biosciences Holdings, Inc. (NASDAQ: SNTI), detailing its current stock price, historical performance, analyst forecasts, and key financial metrics. It highlights the company's earnings, revenue, market capitalization, and volatility, whi

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 05:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI

This article displays the "Price to sales forward" metric for Senti Biosciences Holdings, Inc. (NASDAQ: SNTI). It is a brief financial data point from TradingView, indicating that the market for SNTI was closed with no trades when this information was presented. The article is a

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 04:09
Source
TradingView
TradingKey Direct company coverage

Senti Biosciences Inc (SNTI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Senti Biosciences Inc (SNTI), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. SNTI's current price momentum score is 6.28, and it is trading between a resistance lev

Tone
Positive 59/100
Event
Market update
Published
26 Jun 2026 03:40
Source
TradingKey
TradingView Direct company coverage

SNTI Forecast — Price Target — Prediction for 2027

This article provides a forecast for Senti Biosciences Holdings, Inc. (SNTI) stock, including price targets from three analysts, with a maximum estimate of $15.00 and a minimum of $12.00. It also covers SNTI's current price, historical performance, volatility, market capitalizati

Tone
Neutral 50/100
Event
Guidance
Published
25 Jun 2026 13:11
Source
TradingView
Stock Titan Direct company coverage

Senti Biosciences (SNTI) registers 15.97M shares tied to May 2026 notes

Senti Biosciences (SNTI) has registered 15.97 million shares of common stock for resale, tied to Senior Secured Convertible Notes issued in May 2026. This move, while not generating direct proceeds for the company, represents a significant potential dilution, as the shares could

Tone
Negative 36/100
Event
Market update
Published
18 Jun 2026 21:11
Source
Stock Titan
TradingKey Direct company coverage

Senti Biosciences Inc (SNTI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Senti Biosciences Inc (SNTI) has an earnings forecast score of 8.50, placing it 108th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $12.00 for SNTI, with a "Buy" rating based on the opinions of 4 analysts. The company's EPS for the

Tone
Positive 67/100
Event
Earnings
Published
18 Jun 2026 09:11
Source
TradingKey
TradingKey Direct company coverage

Senti Biosciences Inc (SNTI) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Senti Biosciences Inc (SNTI), noting its current valuation score of 6.82, ranking 295 out of 388 in its industry. It highlights the company's current P/E ratio of -0.65, which is significantly below its recent high and above its recen

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 07:10
Source
TradingKey
TradingKey Direct company coverage

Senti Biosciences Inc (SNTI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Senti Biosciences Inc (SNTI), noting that relevant financial data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly presents the current stock price and marke

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:08
Source
TradingKey
TradingKey Direct company coverage

Senti Biosciences Inc (SNTI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Senti Biosciences Inc (SNTI). It notes that no dividends have been distributed in the past five years and details several upcoming merger-related stock splits scheduled for July 16, 2024, at a 10-to-1 ratio

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 21:08
Source
TradingKey
Finviz Direct company coverage

SNTI - Senti Biosciences Holdings Inc Options

This article provides a comprehensive financial overview of Senti Biosciences Holdings Inc (SNTI), detailing its current stock performance, key financial metrics, and company statistics. It includes data on market capitalization, income, sales, analyst recommendations, and variou

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jun 2026 20:51
Source
Finviz
Finviz Direct company coverage

SNTI - Senti Biosciences Holdings Inc Stock Price and Quote

This page provides a detailed financial overview and news feed for Senti Biosciences Holdings Inc (SNTI). It includes key financial metrics, stock performance data, analyst ratings, and a chronological list of recent company news releases, focusing on clinical trial advancements

Tone
Positive 66/100
Event
Analyst action
Published
07 Jun 2026 08:12
Source
Finviz
Market source Direct company coverage

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

Senti Biosciences Holdings announced its Q1 2026 financial results, highlighting significant progress in its SENTI-202 program for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML), which is now advancing into a pivotal phase after positive FDA feedback supporting a single-arm

Tone
Positive 71/100
Event
Earnings
Published
29 May 2026 17:12
Source
Market source
Stock Titan Direct company coverage

Senti Biosciences (SNTI) sells $10M notes, outlines up to $60M SENTI-202 CVR

Senti Biosciences, through its subsidiary Senti Holdings, has sold $10.0 million in senior secured convertible notes to Celadon Partners SPV 24, as per a previously announced agreement. The company also detailed potential future "Subject Transactions," which could include additio

Tone
Neutral 50/100
Event
Market update
Published
26 May 2026 20:10
Source
Stock Titan